

PATIENT PRESENTING CLINICAL SIGNS

Frankie Ross

History: Recheck echo. Increased coughing - improved with Lasix. History of seizures.
-Current Medications: Lasix 10 BID, Vetmedin 2.5 BID, Zonisamide 100 BID, Phenobarb 16.2 BID, Clavamox.

SPECIES

Canine

-Pertinent previous echo findings (7/2021 MML): Moderate MR, moderate LAE, mild LVE, mild TR. LA: 3.1, LV: 4.0. Pimobendan recommended at that time.

BREED

Lhasa Apso

RADIOGRAPHIC FINDINGS *NOTE: Images submitted for supplemental cardiac information only.
Cardiomegaly with concern for CHF.

SEX

Male Neutered

ECHOCARDIOGRAM FINDINGS

2D, m-mode, color flow and doppler imaging is available. Diffuse thickening of mitral valve leaflets with mild prolapse into the left atrial lumen. Severe eccentric mitral regurgitation with severe left atrial dilation. Normal MR velocity. Severe LV dilation with hyperdynamic myocardial function. The tricuspid valve appears mildly thickened with mild TR. Mild right heart enlargement suggest early pulmonary hypertension. The pulmonic and aortic valves are normal in morphology and mobility. Normal aortic and pulmonic outflow velocities with laminar flow. No AI or PI. No pericardial or pleural effusion noted. No obvious cardiac masses.

AGE

12 years

CARDIAC CHART

WEIGHT

17.7lbs

INTERPRETED BY

Maggie Machen Lamy, DVM, DACVIM (Cardiology)

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	5.2	NM	2.1	2.9	33	62	0.6
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	150	1.2	1.0	8.0	4.0	4.5	3.0
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
BODY WEIGHT DEPENDENT PARAMETERS				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
*Note: All measurements based upon multi-modal images and methods. An average value is reported.				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
				35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
				40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

HOSPITAL NAME

The Village Veterinarian

REFERRING VET

Dr. Longenecker

INVOICE


24691

DATE

6/9/22

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

Chronic degenerative valve disease persists with evidence of progression. Moderate disease has become severe with significant left heart enlargement. Mild right heart enlargement suggest early pulmonary hypertension. No additional issue are identified.



PATIENT

Frankie Ross

SPECIES

Canine

BREED

Lhasa Apso

SEX

Male Neutered

AGE

12 years

WEIGHT

17.7lbs

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

IMAGING PERFORMED BY

Rebekah Jakum, CVT
ARDMS/RVT

HOSPITAL NAME

The Village
Veterinarian

REFERRING VET

Dr. Longenecker

INVOICE

24691

DATE

6/9/22

In light of the prior clinical signs, chest radiographs and severity of disease on echocardiogram, congestive heart failure is confirmed, and medications are warranted lifelong as below. Monitoring of sleeping respiratory rates will be paramount to screen for congestive heart failure at home. Cough suppression to improve QOL can also be considered (hydrocodone, 0.2-0.4mg/kg up to q4-6h PRN) for any residual mechanical cough in the face of normal sleeping respiratory rates. The average survival time of canine patients with active pulmonary edema is 8-9 months on medications, however they generally are able to maintain a good quality of life for that period. Patient will always be at risk for recurrent CHF, development of arrhythmias/LA tear, syncope and/or sudden death in the future.

Omega fatty acid supplementation and mild salt restriction may also be of some long-term benefit. Monitor for acute progression of the cough, labored breathing, exercise intolerance or collapse episodes in the future.


PLAN

Continue Pimobendan 0.3mg/kg PO q12h. Continue Furosemide 1-2mg/kg PO q12h. Institute spironolactone 1-2mg/kg PO q12h.

Monitor SRRs at home. Monitor renal values and BP in 10-14 days, then every 3-4 months while on diuretics. If doing well and BP >130mmHg, institute ACEI 0.5mg/kg PO q12h. Consider hydrocodone if needed for QOL.

Recommend conservative monitoring with a recheck echocardiogram in 6 months, sooner if any development of associated clinical signs occurs in the interim.

IMAGES



The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

Maggie Machen Lamy, DVM
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)
info@sonopath.com